Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 8, 2019

Pharma industry private equity deals in Q4 2018 total $1.74bn globally

Total pharma private equity deals in Q4 2018 worth $1.74bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 68.7% over the previous quarter and a drop of 69.2% when compared with the last four-quarter average, which stood at $5.64bn.

Comparing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $1.09bn. At the country level, Sweden topped the list in terms of deal value at $761.76m.

In terms of volumes, North America emerged as the top region for pharma private equity deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of private equity deals activity in Q4 2018 was the United States with 18 deals, followed by the United Kingdom with four and India with four.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

In 2018, as of the end of Q4, pharma private equity worth $23.01bn were announced globally, marking an increase of 29.8% year on year.

Pharma private equity deals in Q4 2018: Top deals

The top five pharma private equity deals accounted for 68.7% of the overall value during Q4 2018.

The combined value of the top five pharma private equity deals stood at $1.19bn, against the overall value of $1.74bn recorded for the quarter.

The top announced pharma private equity deal tracked by GlobalData in Q4 2018 was EQT VIII’s $692.24m private equity deal with Karo Pharma.

In second place was NovaQuest Capital Management and RTW Investments’ private equity deal with Roivant Sciences for $200m and in third place was Deerfield Management’s $125m private equity deal with Tris Pharma.

AJS BioTree Healthcare Fund, Atinum Investment, Black Diamond Ventures, Cota Capital Management, KTB Network, Nikon, Paxion Capital Partners, Sequoia Capital, Shangbay Capital, Variance Development Partners and Walden Riverwood Ventures’ $95m private equity deal with Berkeley Lights and BDC Capital, Boxer Capital, Domain Associates, Fonds de solidarite FTQ, Forbion Capital Partners Management Services, Go Capital, Novo Holdings, Pappas Capital, RTW Investments, Tekla Capital Management and Venrock Healthcare Capital Partners’ private equity deal with Milestone Pharmaceuticals for $80m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU